Salk Institute researchers and collaborators introduced Superb-seq, a single-cell platform coupling Cas9 edit detection with transcriptome profiling to map both on- and off-target effects. The method integrates CRISPR editing readouts with single-cell RNA sequencing to reveal which unintended edits occur and how they alter gene expression. In testing described in Nature Methods, Superb-seq detected numerous edit sites in leukemia cells, including a larger fraction of off-target events than typically expected from standard workflows. The authors also report that gene expression changes can appear even when edit locations are invisible to conventional detection methods. The development is positioned as a tool for basic research, drug development, and personalized medicine—addressing a key bottleneck in translating gene editing, where off-target activity remains a central safety and efficacy question.